Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 - ResearchAndMarkets.com

2023-04-04
Business Wire
DUBLIN--(BUSINESS WIRE)--The "Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023" report has been added to ResearchAndMarkets.com's offering.
'Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023'
The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies.
This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2016.
There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.
Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.
Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.
The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all joint venture deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of joint venture dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in joint venture as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of joint venture deals. The chapter includes numerous case studies to enable understanding of joint venture deals.
Chapter 4 provides a review of the leading Joint venture deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active Joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of Joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Joint venture deal.
The appendices to the report includes a comprehensive listing of all Joint venture deals announced since 2016. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in Joint venture dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances.
Key benefits
Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 provides the reader with the following key benefits:
In-depth understanding of joint venture partnering deal trends since 2016, with real life case studies
Comprehensive listing of all joint venture deals since 2016, together with deal terms, value and press release
Comprehensive access to actual joint venture contracts entered into by the world's life science companies
Insight into the terms included in a joint venture agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading life science companies worldwide.
Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 includes:
Trends in joint venture dealmaking in the biopharma industry since 2016
Case studies of real-life joint venture deals
Comprehensive listing of joint venture deals since 2016
Access to joint venture contract documents
The leading joint venture deals by value since 2016
Most active joint venture dealmakers since 2016
The leading joint venture partnering resources
In Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 available deals and contracts are listed by:
Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.
The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive access to available contract documents for joint venture deals.
Companies Mentioned
1717 Life Science Ventures
A*STAR Agency for Science
Technology and Research
A*STAR Institute of Microelectronics (IME)
A*STAR' Institute of Molecular and Cell Biology
Abzena
Accuray
Acnos Pharma
Adept Neuro
AKESOgen
Aleva Neurotherapeutics
Allied-Bristol Life Sciences
Allied Minds
Altus Formulation
Alzheimer's Association
Alzheimer's Research UK
Amyris
Antitope
Apax Partners
Arbele
ARCH Personalized Medicine Initiative
Arvinas
Athenex
Atomwise
Auramedi Farmaceutica
AUT Roche Diagnostics Laboratory
AUT University
Auxly Cannabis Group
Avalon GloboCare
Bayer
Baylor Miraca Genetics Laboratories
B Braun
B Braun CeGaT
Becton Dickinson
BeiGene
Betaliq
BevCanna
BHB TherapeuticsBHB Therapeutics
Bill and Melinda Gates Foundation
Biodist
BioFields
Biohealth Innovation
biologistex CCM
BioMed X Innovation Center
Biomerics
Blockshine Technology
Bloom Burton
BLP Management
Buck Institute for Age Research
Button Capital
Cancer Research Technology
Cannabis Biocare
Cannabis Therapeutics
CannAmerica Brands
CannaRoyalty
Cardio3 Biosciences Asia Holdings
Catapult Therapy TCR
CB2 Therapeutics
CBDistribution
CeGaT
Cell Therapy Catapult
Celyad
Centene
Center for Genetic Engineering and Biotechnology (Cuba)
Centre for Commercialization of Regenerative Medicine (CCRM)
Centro de Inmunolgia Molecular
Children's Medical Research Institute
China-Israel Biological Technology
China-Singapore Guangzhou Knowledge City
China Isotope And Radiation
Chinese Future Industry Investment Fund
Chongqing PSK-Health Sci-tech Development
City of Hope
CJ CheilJedang
Cloaked Therapeutics
Cohen Veterans Bioscience
Cold Spring Harbor
Colibri Heart Valve
Collagen Solutions Plc
Concentrics Research
Consortium AI
Corestone Biosciences
Cornerstone Animal Health
Corning
Cre8ive
CureCell
Dance Biopharm
David Snow
Deerfield Management
Demetra
Denka
Denka-KEW Genomics
Dixi
DolCas-Tenshi Bioceuticals
DolCas Biotech
Dona Blanca
Dr. Walter Bell
Eastern Capital
EMD Millipore
EmoCellix
Enova Illumination
ExCellThera
Facebook
Fedecore
FJ Pharma
Flexpoint Ford
Fonterra
Fox Chase Cancer Center
Frazier Healthcare Ventures
Fuzionaire Radioisotope Technologies
G-treeBNT
Genomix Scientific
Gentag
German Research Center for Artificial Intelligence
Gerresheimer
GHO Capital
For more information about this report visit https://www.researchandmarkets.com/r/laae8e
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。